The target of locostatin, a small-molecule inhibitor of cell movement, has been identified as RKIP, a Raf-1 kinase modulator [1] . In addition to advancing our understanding of cell locomotion, this work represents a major landmark in the development of chemical genetics.
teraction is kinase independent, so it's not clear how inhibition of RKIP, which is expected to result in activation of Raf-1 kinase activity, suppresses cell locomotion.
An alternative mechanism is suggested by the demonstration that, when phosphorylated by protein kinase C, RKIP ceases to bind Raf-1, and instead binds to and inhibits G protein-coupled receptor kinase 2 (GRK2 [9] ) ( Figure 1 ). GRK2 is a serine/threonine kinase known to downregulate a variety of G protein-coupled receptors [10] . Significantly, such receptors play a key role in cell locomotion in other cell types [2] . Further, in leukocytes, increased GRK2 activity is associated with suppression of cell locomotion [11] , while GRK2 loss is correlated with increased cell locomotion [12] . In this case, the locostatin-RKIP interaction would have to disrupt RKIP-GRK2 binding, a point which needs to be tested.
In addition to providing important insight into cell locomotion, this work also fulfills the promise of chemical genetics as an approach with many of the strengths of classic genetics, but which is not limited to a few model systems. To be sure, the chemical genetic approach can suffer from a relative lack of specificity and reduced potency of many small-molecule effectors and, in many cases, difficulty in cellular target identification. Nevertheless, this report [1] , when considered with the authors' previous work [3] , satisfies several key criteria that define a successful genetic study.
First, classic forward genetics can work with any process, no matter how complex, as long as an appropriate screen is employed. While much recent effort in chemical genetics has focused on the use of automated, high-throughput screens, with a particular bias toward biochemical readouts [13, 14] , here a screen based on visual inspection of epithelial cell migration was performed. Manual screens are inherently slower and less objective than automated screens; however, they are also simpler and higher content [15] , and their potential for success is confirmed by the identification of locostatin. Given the relative accessibility of manual screens to the average investigator, and the fact that small-molecule libraries can now be obtained commercially, or even for free, it follows that chemical genetics is an avenue available to anyone who cares to try it.
Second, genetic studies have the potential to identify any player that controls a particular process, regardless of that player's mode of action. However, many previously identified small-molecule inhibitors target enzymes. Further, of those that target nonenzymes by disrupting protein-protein interactions, most, if not all, of them were identified in screens directed at finding agents to disrupt binding of two particular proteins (e.g., Myc and Max; see [13] ). Locostatin not only targets a nonenzyme (RKIP), disrupting the interaction of RKIP with Raf-1, but was also identified in a targetblind approach. This indicates that small molecules may prove generally useful as regulators of nonenzymes by disrupting protein-protein interactions and, by extension, that this approach can potentially identify any relevant player in a pathway.
Third, the ideal genetic study is definitive, with a par- 
